Compelling evidence suggests that both myoinositol and D-chiro-inositol (DCI) can counteract downstream consequences of insulin resistance for managing PCOS. On one hand, DCI facilitates insulin activity mainly on non-ovarian tissues, while myoinositol modulates glucose metabolism and FSH-signalling to show specific effects on the ovary. Moreover, myoinositol modulates steroid metabolism through non-insulin-dependent pathways to improve ovarian […]